Interactive Features

Quiz

Second-Line Treatment Outcomes Among Patients With FL or MZL

12/07/2023

True or False: According to a 7-year follow-up of the phase 3 SELENE study, the overall survival in the ibrutinib-chemotherapy arm and placebo chemotherapy arm were promising, which indicates encouraging outcomes among patients in the second...

True or False: According to a...

12/07/2023

Oncology

Quiz

Treating Non-Hodgkin Lymphoma With Re-Priming Radiation Therapy After CAR T

11/14/2023

True or False: Results from a phase 1 trial on re-priming radiation therapy for R/R non-Hodgkin lymphoma, including DLBCL and FL, indicated that early salvage focal definitive dose radiation to sites of incomplete response after CAR T-cell...

True or False: Results from a...

11/14/2023

Oncology

Quiz

Measuring Risk of Therapy-Related Myeloid Neoplasms Among Patients With FL or DLBCL

11/06/2023

True or False: Findings from a 15-year SEER-Medicare study identified that prior histories of autoimmunity and the use of granulocyte colony-stimulating factors significantly decreased the risk of development of therapy-related...

True or False: Findings from a...

11/06/2023

Oncology

Quiz

Epcoritamab Plus Rituximab and Lenalidomide for R/R FL

10/30/2023

True or False: The combination of epcoritamab plus rituximab and lenalidomide among patients with R/R follicular lymphoma demonstrated significantly high response rates, according to findings from the phase 1/2 EPCORE NHL-2 trial.

True or False: The combination...

10/30/2023

Oncology

Quiz

Treating Follicular Lymphoma With Mosunetuzumab Monotherapy

10/24/2023

Updated results from the pivotal phase 2 GO29781 study on mosunetuzumab monotherapy among patients with relapsed/refractory follicular lymphoma demonstrated an overall response rate of approximately ___ among patients receiving this...

Updated results from the pivotal...

10/24/2023

Oncology

Quiz

Quiz: Triplet Therapy Combination for R/R Follicular Lymphoma

03/23/2023

True or False: The triplet therapy combination of epcoritamab and rituximab and lenalidomide was active in patients with R/R follicular lymphoma, including those who might be more difficult to treat, such as refractory patients and those who...

True or False: The triplet...

03/23/2023

Oncology

Quiz

Quiz: Epcoritamab Plus Rituximab and Lenalidomide Treatment for Relapsed/Refractory Follicular Lymphoma

03/23/2023

True or False: In a study exploring subcutaneous epcoritamab combined with rituximab and lenalidomide treatment for patients with relapsed/refractory follicular lymphoma, the majority of patients who had a partial response at first assessment...

True or False: In a study...

03/23/2023

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology